The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Plutonium-241 is a beta emitter with a half-life of 14.33 years, corresponding to a decay of about 5% of 241Pu nuclei over a one-year period. This decay has a Q-value of only 20.8 keV, and does not emit gamma rays. The longer spent nuclear fuel waits before reprocessing, the more 241Pu decays to americium-241, which is nonfissile (although fissionable by fast neutrons) and an alpha emitter with a half-life of 432.6 years; 241Am, which does emit gamma rays, is a major contributor to the radioactivity of nuclear waste on a scale of hundreds to thousands of years. In its fully ionized state, the beta-decay half-life of 241Pu94+ decreases to 4.2 days, and only bound-state beta decay is possible. Plutonium-241 also has a rare alpha decay branch to uranium-237, occurring in about 0.0025% of decays. Unlike its usual beta decay, this can emit gamma rays, X-rays, and associated electrons.
The statue's iconography is frequently compared to that of the carmen saeculare by Horace, and commemorates Augustus's establishment of the Pax Romana. The breastplate is carved in relief with numerous small figures depicting the return, thanks to the diplomacy of Augustus, of the Roman legionary eagles or aquilae lost to Parthia by Mark Antony in the 40s BC and by Crassus in 53 BC. The figure in the centre, according to the most common interpretation, is the subjected Parthian king (Phraates IV) returning Crassus's standard to an armored Roman (possibly Tiberius, or symbolically Mars Ultor or the incarnation of the ideal legionary). Another theory sees in the male figure the ideal incarnation of the Roman legions. This was a very popular subject in Augustan propaganda, as one of his greatest international successes, and had to be especially strongly emphasized, since Augustus had been deterred by Parthian military strength from the war which the Roman people had expected and had instead opted for diplomacy. Below the armed figure we can see a dog, or probably a wolf or, according to archaeologist Ascanio Modena Altieri, a she-wolf, nurse of Romulus and Remus. To the left and right sit mourning female figures; the figure on the one side with a sheathed sword personifies the peoples in the East (and possibly the Teutons) forced to pay tribute to Rome, and the one on the other side with an unsheathed sword personifies the subjected peoples (the Celts). From the top, clockwise, we see:
== History == The nitrophenyl ethers are a well-known class of herbicides, the oldest member of which was nitrofen, invented by Rohm & Haas and first registered for sale in 1964. This area of chemistry became very competitive, with the Mobil Oil Corporation's filing in 1969 and grant in 1974 of a patent to the structural analog with a COOCH3 group adjacent to the nitro group of nitrofen. This product, bifenox, was launched with the brand name Mowdown in 1981. Meanwhile, Rohm & Haas introduced acifluorfen (as its sodium salt with brand name Blazer) in 1980, having developed it under the code number RH-6201. It had much improved properties including a wider spectrum of herbicidal effect and good safety to soybean crops. The first patent for the material was published in December 1975, although an earlier Belgian patent published in September 1973 had described related chemistry.
Sources: en.wikipedia.org
These are commonly used in shipping, because they sublime relatively slowly due to a low ratio of surface area to volume. Pellets are around 1 cm (0.4 in) in diameter and can be bagged easily. This form is suited to small scale use, for example at grocery stores and laboratories where it is stored in a thickly insulated chest. Density of pellets is 60–70% of the density of blocks. Dry ice is also produced as a byproduct of cryogenic air separation, an industry primarily concerned with manufacturing extremely cold liquids such as liquid nitrogen and liquid oxygen. In this process, carbon dioxide liquefies or freezes at a far higher temperature compared to that needed to liquefy nitrogen and oxygen. The carbon dioxide must be removed during the process to prevent dry ice from fouling the equipment, and once separated can be processed into commercial dry ice in a manner similar to that described above.
Tempeh can also be differentiated according to its degrees of maturity (i.e. the mycelium's growth/age). Tempe mondhol is a tempeh that is not fully fermented, that is, the mycelium has not fully covered the surface. The taste of the beans is more solid and profound. Sometimes tempeh is left to ferment further, creating more pungent varieties: tempe wayu (day-old tempeh), i.e. when the tempeh starts to age; tempe semangit (a few-days old tempeh), i.e. when the tempeh becomes yellowish, a bit slimy, and the smell becomes more potent; and tempe bosok (lit. 'rotten tempeh'), when the mycelium has acquired a blackened coloration and the product has a putrid smell. Some types of tempeh are made of ingredients that would be otherwise wasted if not used. According to traditional Javanese customs, wasting food is deemed as a sign of disrespect to Nature and other beings, and encourages efforts to use every part of an ingredient. The wrappings used in tempeh making can contribute to its flavor and aroma. Though some prefer the traditional banana, waru or teak leaf, readily available plastic sheet wrappings have been increasingly widely used.
Until about the time of the Meiji Restoration in 1868, cattle were used only as draught animals, in agriculture, forestry, mining and transport, and as a source of fertilizer. Milk consumption was unknown, and – for cultural and religious reasons – meat was not eaten. Cattle were highly prized and valuable, too expensive for a poor farmer to buy. Japan was effectively isolated from the rest of the world from 1635 until 1854; there was no possibility of the intromission of foreign genes to the cattle population during this time. In western Japan during the Edo period (1603–1867), superior cattle were produced by aggressive inbreeding, and the superior bloodlines were called "tsuru" (蔓, lit. 'vine'), and cattle with superior bloodlines (tsuru-ushi, lit. 'vine cattle') were traded at high prices. Famous tsuru include the Takenotani tsuru (Okayama Prefecture), Bokura tsuru (Shimane Prefecture), Iwakura tsuru (Hiroshima Prefecture), and Shusuke tsuru (Hyōgo Prefecture). In Japan, where meat eating was frowned upon and the use of milk was not widespread, cows in the Edo period were primarily work cattle that plowed the fields, so a good cow in this period meant one that was healthy and obedient.
Ohanin, a minor vespryn protein component specific to this species, causes hypolocomotion and hyperalgesia in experimental mice. It is believed that it contributes to neurotoxicity on the central nervous system of the victim.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.